Please assess the completion status of the following clinical trial:

Trial Title: Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subject must understand the purpose of the study and be willing to adhere to the study schedule and procedures described in this protocol.~* Subject must be 25-64 years of age (inclusive) on the day of signing consent.~* Subject must be diagnosed with rheumatoid arthritis as defined by the American College of Rheumatology.~* Subject must be on stable regimen for treatment of rheumatoid arthritis for a minimum of 90 days prior to study start.~* Subject must report a wake time after sleep onset (WASO) of greater than or equal to 45 minutes and less than or equal to 6.5 hours of total sleep time at least three times a week over the previous month and symptoms of insomnia must post date onset of rheumatoid arthritis.~* Subject physical exam must show no clinically significant abnormal findings (other than those related to rheumatoid arthritis) at screening.~* Subject must have no clinically significant abnormal laboratory findings at screening (other than those related to rheumatoid arthritis).~* Subject must have no clinically significant ECG abnormalities at screening.~Exclusion Criteria~* Subject has diagnosis of fibromyalgia, or juvenile rheumatoid arthritis.~* Subject has history of circadian rhythm disorder, or travels across \>3 time zones on a regular basis.~* Female subject is pregnant, lactating or within 6-months post partum.~* Subject has a history of drug or alcohol abuse or dependence in the past 2 years or positive urine drug test at screening.~* Subject has clinically significant unstable medical abnormality or unstable chronic disease (other than insomnia and rheumatoid arthritis) including severe cardiac, renal, or hepatic or respiratory disease, seizure disorder.~* Subject has participated in any investigational drug study within 30 days prior to screening or plans to participate in any investigational drug study during participation in this study.~* Subject has a history of malignancy within 5 years, or current malignancy, except for non-melanoma skin cancer.~* Subject has a current primary psychiatric diagnosis of any of the following disorders: dementia, delirium, schizophrenia, psychosis, other psychotic disorders, dysthymic disorder; major depressive disorder, bipolar disorders; cyclothymic disorder, other mood disorders, primary anxiety disorders, primary panic disorders, or any nocturnal panic disorder.~* Subject has any of the following Personality Disorders diagnoses: schizotypal, schizoid, borderline personality disorder; or any other personality disorder that would compromise the investigator's ability to evaluate the safety and efficacy of the study medication.~* Subject has difficulties in sleep initiation or maintenance associated with known medical diagnosis \[e.g. sleep apnea\]; diagnosed and untreated restless leg syndrome (RLS) or periodic leg movement syndrome (PLMS).~* Subject has used any drugs known or suspected to affect hepatic or renal clearance capacity within a period of 30 days prior to screening.~* Subject reports consumption of more than two alcoholic beverages daily, 14 or more alcoholic beverages weekly, or five or more alcoholic beverages on any given day.~* Subject is a rotating or third/night shift worker.~* Subject is a staff member or relative of a staff member.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): eszopiclone 3 mg
- 2 (Type: PLACEBO_COMPARATOR): placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete